StockNews.com Initiates Coverage on Heska (NASDAQ:HSKA)

Analysts at StockNews.com initiated coverage on shares of Heska (NASDAQ:HSKA – Get Rating) in a research report issued to clients and investors on Tuesday. The brokerage set a “hold” rating on the medical research company’s stock.

Several other brokerages also recently commented on HSKA. Alliance Global Partners downgraded shares of Heska from a “buy” rating to a “neutral” rating in a report on Monday, April 3rd. Piper Sandler cut their price target on shares of Heska from $165.00 to $150.00 in a report on Thursday, March 2nd. Finally, Morgan Stanley upped their price target on shares of Heska from $58.00 to $120.00 and gave the company an “equal weight” rating in a report on Tuesday, April 4th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $137.25.

Heska Stock Performance

Heska stock opened at $116.31 on Tuesday. The company’s 50-day moving average price is $109.78 and its 200-day moving average price is $86.56. Heska has a twelve month low of $57.83 and a twelve month high of $118.00. The company has a quick ratio of 4.12, a current ratio of 5.64 and a debt-to-equity ratio of 0.23. The company has a market cap of $1.27 billion, a PE ratio of -60.26 and a beta of 1.60.

Heska (NASDAQ:HSKA – Get Rating) last posted its earnings results on Tuesday, February 28th. The medical research company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of $0.17 by $0.05. Heska had a negative net margin of 7.86% and a positive return on equity of 0.94%. The firm had revenue of $66.34 million for the quarter, compared to the consensus estimate of $63.96 million. On average, equities research analysts forecast that Heska will post 0.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Heska

Several large investors have recently added to or reduced their stakes in the stock. Signaturefd LLC lifted its position in shares of Heska by 146.3% in the 4th quarter. Signaturefd LLC now owns 399 shares of the medical research company’s stock worth $25,000 after purchasing an additional 237 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of Heska by 270.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 315 shares of the medical research company’s stock worth $31,000 after purchasing an additional 230 shares during the period. Quantbot Technologies LP lifted its position in shares of Heska by 245.6% in the 3rd quarter. Quantbot Technologies LP now owns 508 shares of the medical research company’s stock worth $37,000 after purchasing an additional 361 shares during the period. Point72 Hong Kong Ltd purchased a new stake in shares of Heska in the 1st quarter worth approximately $57,000. Finally, PNC Financial Services Group Inc. lifted its position in shares of Heska by 18.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,673 shares of the medical research company’s stock worth $104,000 after purchasing an additional 261 shares during the period. 99.01% of the stock is owned by hedge funds and other institutional investors.

Heska Company Profile

(Get Rating)

Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through the North America and International segments. The North America segment includes the United States, Canada, and Mexico. The International segment involves Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland.